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MinireviewMetastatic Potential: Generic
Predisposition of the Primary Tumor
or Rare, Metastatic Variants—Or Both?
tern of gene expression in the primary tumors that is
predictive of their malignant potential (see Figure 1a).
That conclusion could fit with the general idea of clonal
tumor progression (Nowell, 1976) toward malignancy
(i.e., invasion and metastasis). Alternatively, the “good
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prognosis” and “poor prognosis” signatures could re-Cambridge, Massachusetts 02139
flect independent evolution of the two classes of primary
tumors. It has been argued further (Bernards and Wein-
berg, 2002; van de Vijver et al., 2002; Ramaswamy etMetastasis is a rare event. Does it arise from rare,
al., 2003) that these results are in conflict with the ideavariant, highly metastatic cells or does a primary tumor
that metastases arise from rare, highly metastatic vari-progress to a premalignant state from which metasta-
ants within the primary tumor. However, by their veryses arise stochastically without further changes in
nature, DNA array analyses of bulk primary tumor sam-gene expression? Arguments and evidence have been
ples cannot detect rare variant cells. Just because theadduced to support either position. A paper in this
array data fail to detect, and do not themselves raisemonth’s Cancer Cell (Kang et al., 2003) and other argu-
the need to invoke, rare metastatic variant cells, thatments instead suggest models combining features of
does not mean that such cells do not exist and play anboth.
important role. In fact, it has been shown repeatedly
that cells isolated from metastases are frequently more
highly metastatic than the bulk population of cells fromHow do metastases arise from primary tumors? This
primary tumors (Fidler and Kripke, 1977; Hart and Fidler,question is of considerable importance both for clinical
1981; Fidler, 1990; Clark et al., 2000). That is, one candiagnosis and therapy and for an understanding of the
isolate highly metastatic variants by in vivo selectionunderlying molecular and cellular mechanisms of cancer
or merely by subcloning, and their elevated metastaticprogression. Despite long-standing recognition of the
potential persists on culture. Whether these variantsimportance of this question, we still cannot provide an
arise by genetic or epigenetic mechanisms, they provideadequate answer. However, our current understanding
evidence for an alternative model for metastatic pro-of molecular cell biology and the availability of DNA
gression (See Figure 1b).microarrays, which allow genome-wide analyses of gene
In an elegant paper in the latest issue of Cancer Cell,expression profiles, are providing a wealth of new infor-
Kang et al. (2003) present results that help to reconcilemation relevant to the question of metastatic potential
the two models. They too were investigating metastaticand progression. Along with the new information comes
potential in human breast carcinoma cells. Using thecontroversy about its interpretation.
human breast cancer cell line, MDA-MB-231, (originallySeveral recent analyses of human tumor material us-
derived from a patient with disseminated breast cancer),ing DNA microarrays have shown that primary tumors
injected into immunodeficient mice, they were able tocan be classified into those with “good” or “poor” prog-
observe metastases to bone and to the adrenal medulla.noses based on their patterns of gene expression (e.g.,
They reisolated human cells from the osteolytic boneSorlie et al., 2001). In particular, a subset of breast tu-
metastases and found that they could isolate lines ofmors can be identified as being predisposed to metasta-
cells with stably elevated metastatic potential. Further-sis, even when no clinical evidence for metastatic spread
more, lines selected in vivo for metastasis to bone or
was apparent at the time of tumor resection (van’t Veer
to adrenals retained their tissue selectivity. Kang et al.
et al., 2001; van de Vijver et al., 2002). In these two
then performed DNA array analyses on a series of lines
papers, a “gene expression signature” was defined that isolated from the bone metastases and were able to
predicts the probability of later appearance of metasta- define a gene expression signature (102 genes) that cor-
ses. It has also been reported that metastases and pri- related well with potential for osteolytic bone metasta-
mary mammary tumors from the same individual show ses. They also analyzed the pattern of expression of the
similar gene expression profiles (Perou et al., 2000) and “poor prognosis” gene signature defined by van’t Veer
that premalignant stages of breast cancer progression et al. (2001) using clinical material. All the MDA-MB-231
show expression profiles similar to invasive ductal carci- isolates, whether of high or low metastatic potential to
noma (Ma et al., 2003; Porter et al., 2003). Perhaps most bone, fitted with the poor prognosis pattern. That is, the
surprisingly, a survey of a wide range of primary adeno- starting cell culture in the experiments of Kang et al.
carcinomas in comparison with metastases from a simi- had already undergone the transition defined by van’t
lar set of adenocarcinomas uncovered a “metastatic Veer et al. Nonetheless, the cells could be divided into
gene signature” common to many different tumor types poorly and highly metastatic variants by in vivo selection
(Ramaswamy et al., 2003). This “metastatic gene signa- and the highly metastatic variants had an additional
ture” could be detected in some primary tumors and “metastatic signature” overlaid on the “poor prognosis”
had significant prognostic value. signature.
These data all indicate that there is some global pat- Kang et al. went on to test whether any of the genes
defined by their “bone metastasis signature” were actu-
ally causal in enhancing metastasis to bone. They over-*Correspondence: rohynes@mit.edu
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Figure 2. Multiple Steps in Metastatic Progression
Although the poor prognosis signature has generally been interpre-
ted as reflecting a difference in the tumor cells themselves, that is
unlikely to be the full picture. An alternative, though not mutually
Figure 1. Contrasting Models for the Development of Metastatic exclusive, model is that some of the differences in tumors with poor
Potential within Primary Tumors prognosis reflect infiltration of host cells (green), angiogenesis (red),
or deposition of matrix (black)—collectively a “stromal response.”(a) Several studies show that primary tumors with metastatic poten-
Any of these events could precede or follow any global change intial can be distinguished from those without by a difference in overall
gene expression by the tumor cells and the appearance of highlygene expression profiles, and other studies show that metastases
metastatic variants (purple cells) and could contribute to their sur-share some patterns of gene expression with the primaries from
vival and/or their metastatic spread. At the site of the metastasis,which they originate. The simplest interpretations of these findings,
the tumor cells could well need and/or induce a similar stromaldiagrammed here, are (1) that there is a clonal progression from a
response to that in the primary tumor, as well as interacting withnonmalignant state (light blue) to a malignant state (dark blue), or
cells specific to the site of the metastasis (yellow).(2) that the two types of primary tumor arise independently with
For this model to be consistent with the similarity in overall genediffering properties. In either case, it has been argued that metasta-
expression profiles between metastases and tumors with poor prog-ses are rare, stochastic events not requiring further genetic change.
nosis, the metastatic variant cells (purple) should not differ greatlyMore sophisticated versions of this model will be discussed later—
from the cells in the primary tumor (dark blue). In other words, thesee Figure 2.
number of genes with altered expression required to generate a(b) Other studies demonstrate the existence within primary tumors
highly metastatic variant should be small. That has, in fact, beenof rare, highly metastatic variants (red) that give rise to metastases.
the observation (Clark et al., 2000; Kang et al., 2003); one to a few(c) Although it is sometimes argued that these two models are mutu-
overexpressed genes can convert cells from poorly to highly meta-ally exclusive, they are not, and a third model incorporates the two
static, perhaps reflecting “priming” by the global predisposition.sets of data with both a global difference in the primary tumor and
rare variants that eventually give metastases. The order of acquisi-
tion of the global predisposition and the appearance of variant cells
is undefined. Note that the (purple) variant cells that give rise to
expressing one or none of them were less metastaticmetastases are proposed to share the global pattern of gene ex-
than the bulk of the population. Therefore, the parentalpression.
line (derived from a metastatic tumor) contains variant
cells of high and low metastatic capacity, as well as cells
with differing tissue selectivity for metastasis. Theseexpressed genes singly and in combinations in the pa-
rental cells and tested for bone metastatic potential. results are in complete accord with the “preexisting
metastatic variant” model of Fidler. But recall that theThey found a set of four genes (CXCR4, IL-11, CTGF
and MMP1) from their bone-specific metastatic signa- starting cell line also showed the “poor prognosis” ex-
pression profile of van’t Veer et al. Thus, it would seemture that, when coexpressed with the gene for osteopon-
tin (which is overexpressed in both bone and adrenal that both models are correct—in the same system (Fig-
ure 1c).metastases), enhanced metastasis to bone. Each of the
five genes, when expressed alone, was insufficient to Metastasis is a complex process involving many cell
biological steps and presumably requiring many changesconfer high metastatic potential, but, in various combi-
nations, they elevated metastasis to levels similar to in gene expression. Depending on the analysis con-
ducted, one can detect subsets of these changes. Thethose observed with the in vivo selected metastatic vari-
ants. Thus, the bone metastasis signature includes studies that looked for a gene expression signature for
metastatic predisposition found one, whereas those thatgenes causally involved in metastasis to bone.
An important question is whether these highly meta- looked for a signature characteristic of highly metastatic
cells found a different subset. It is worth noting thatstatic variants exist in the bulk population prior to in
vivo selection. Kang et al. isolated subclones of the Kang et al. were able to distinguish cells with propensity
to metastasize to bone or adrenal medulla and theseMDA-MB-231 cell line in vitro, without any selection,
and screened them for levels of expression of the five two groups showed differential gene expression. In an
extensive analysis of human small cell lung cancer ingenes they had analyzed for functional involvement.
They found occasional subclones expressing 3, 4, or 5 mice, Kakiuchi et al. (2003) recently reported differential
gene expression profiles for metastases to each of fourof these genes and tested those for metastatic potential.
Variants expressing 4 or 5 of the genes were highly different sites (lung, liver, kidney, and bone), although
they did not distinguish how much of the differencemetastatic, those expressing only 3 less so, and those
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Hart, I.R., and Fidler, I.J. (1981). Biochim. Biophys. Acta 651, 37–50.arises from tumor responses in different environments.
Kakiuchi, S., Daigo, Y., Tsunoda, T., Yano, S., Sone, S., and Naka-Thus, the metastatic signatures for metastases to differ-
mura, Y. (2003). Mol. Cancer Res. 1, 485–499.ent sites appear to be different.
Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M.,It is well established that tumor cells and surrounding
Cordon-Cardo, C., Guise, T.A., and Massague, J. (2003). Cancerstromal cells interact and influence one another (Hana-
Cell 3, 537–549.
han and Weinberg, 2000; Bissell and Radisky, 2001;
Ma, X.J., Salunga, R., Tuggle, J.T., Gaudet, J., Enright, E., McQuary,Chambers et al., 2002; Fidler, 2002). Indeed, several of
P., Payette, T., Pistone, M., Stecker, K., Zhang, B.M., et al. (2003).
the genes defined by Kang et al. are likely to be involved Proc. Natl. Acad. Sci. USA 100, 5974–5979.
in paracrine interactions between the metastatic mam- Nowell, P.C. (1976). Science 194, 23–28.
mary cells and osteoclasts in the osteolytic metastases Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S.,
which they studied. Because they were studying human Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., et
cell lines in mice, they could distinguish which genes al. (2000). Nature 406, 747–752.
were expressed by the tumor cells. However, that is not Porter, D., Lahti-Domenici, J., Keshaviah, A., Bae, Y.K., Argani, P.,
Marks, J., Richardson, A., Cooper, A., Strausberg, R., Riggins, G.J.,true in the case of the clinical material analyzed in some
et al. (2003). Mol. Cancer Res. 1, 362–375.of the other studies. The genes making up the “poor
Ramaswamy, S., Ross, K.N., Lander, E.S., and Golub, T.R. (2003).prognosis” (van’t Veer et al., 2001; van de Vijver et al.,
Nat. Genet. 33, 49–54.2002) or “metastatic predisposition” (Ramaswamy et al.,
Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen,2003) signatures could represent genes expressed by
H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., et al. (2001).the tumor cells themselves or by “stromal” cells includ-
Proc. Natl. Acad. Sci. USA 98, 10869–10874.
ing vasculature, connective tissue, or immune cells. The
van ’t Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A.,latter model might explain the existence of a “metastatic
Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen,
signature” common to many tumor types. Most likely, A.T., Schreiber, G.J., Kerkhoven, R.M., Roberts, C., Linsley, P.S.,
these prognostic gene signatures reflect several distinct Bernards, R., and Friend, S.H. (2002). Nature 415, 530–536.
sorts or combinations of properties of the primary tumor, van de Vijver, M.J., He, Y.D., van’t Veer, L.J., Dai, H., Hart, A.A.,
predisposing it to metastatic progression (see Figure 2). Voskuil, D.W., Schreiber, G.J., Peterse, J.L., Roberts, C., Marton,
M.J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L.,Whichever model or models apply to this predisposition
van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E.T., Friend,difference, it seems clear that additional clonal change(s)
S.H., and Bernards, R. (2002). N. Engl. J. Med. 347, 1999–2009.occur to yield the final metastatic cell(s)—it is as if the
global predisposition may be necessary to allow expres-
sion of the potential of the rare variants. The order of
these two separable events is currently unclear and may
not matter (see Figure 2). It is also possible that the
relative importance of the global predisposition and the
metastatic variant cells could differ among different tu-
mor types. There is clearly still a lot we do not know
about the mechanisms underlying metastasis. Neither
of the simple models shown in Figures 1a and 1b ex-
plains all the data. The more complex models depicted
in Figure 2 are consistent with the data but are in need
of much further investigation.
The diagnostic, prognostic, and therapeutic value of
the predisposition signatures of primary tumors is
largely unaffected by these mechanistic considerations.
However, experimental analyses such as those of Kang
et al. are an essential complement, allowing investiga-
tion of additional aspects of the metastatic process that
cannot readily be revealed by retrospective analyses of
human tumor samples, and we can expect many new
insights to come from these two complementary ap-
proaches.
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